LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Uždarymo kaina

11.23 -3.44

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.17

Max

11.29

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-154M -183M
Pelnas, tenkantis vienai akcijai	-0.6
Darbuotojai	103
EBITDA	-5.3M -37M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+80.34% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-10

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-53M 3.2B
Ankstesnė atidarymo kaina	14.67
Ankstesnė uždarymo kaina	11.23

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-24 23:46; UTC

Rinkos pokalbiai

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

2026-05-24 23:45; UTC

Rinkos pokalbiai

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-24 23:42; UTC

Rinkos pokalbiai

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

2026-05-24 23:34; UTC

Rinkos pokalbiai

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

2026-05-24 23:11; UTC

Rinkos pokalbiai

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

2026-05-24 22:26; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

2026-05-24 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

2026-05-24 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

2026-05-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

2026-05-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

2026-05-24 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

2026-05-24 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

2026-05-24 22:11; UTC

Rinkos pokalbiai

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

2026-05-24 22:04; UTC

Rinkos pokalbiai

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

2026-05-23 08:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-23 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 21:10; UTC

Uždarbis

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026-05-22 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 19:47; UTC

Uždarbis

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026-05-22 19:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026-05-22 19:10; UTC

Rinkos pokalbiai

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026-05-22 18:38; UTC

Rinkos pokalbiai

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026-05-22 18:35; UTC

Įsigijimai, susijungimai, perėmimai

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026-05-22 18:09; UTC

Rinkos pokalbiai

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026-05-22 17:58; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

80.34% į viršų

12 mėnesių prognozė

Vidutinis 20.27 USD 80.34%

Aukščiausias 30 USD

Žemiausias 9 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.